hVIVO PLC
LSE:HVO
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| UK |
|
hVIVO PLC
LSE:HVO
|
58.4m GBP |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
193.8B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
148.3B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
136.8T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
36B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
282B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
35.2B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.1B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.9B USD |
Loading...
|
|
| CN |
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
165.7B HKD |
Loading...
|
Market Distribution
| Min | -188 120% |
| 30th Percentile | 0% |
| Median | 0% |
| 70th Percentile | 0.1% |
| Max | 10 443.9% |
Other Profitability Ratios
hVIVO PLC
Glance View
hVIVO PLC provides pharmaceutical development services. The firm is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The company provides end-to-end early clinical development services to its client base, which includes global biopharma companies. The company offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The company offers additional clinical field trial services, such as patient recruitment and clinical trial site services. The company runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for hVIVO PLC is 10.3%, which is below its 3-year median of 17.6%.
Over the last 3 years, hVIVO PLC’s Net Margin has increased from -3.2% to 10.3%. During this period, it reached a low of -3.2% on Jun 30, 2022 and a high of 28.8% on Dec 31, 2023.
